Pioneering diagnostics

Cancer

The early and accurate diagnosis of cancer greatly increases the patient's chances of recovery.
 

Cancer is a group of diseases defined by the uncontrolled growth of abnormal cells and the spread of these cells within the patient's body. At least a third of cancers could be avoided by limiting known risk factors (smoking, poor diet, exposure to carcinogenic substances). Early screening and effective and appropriate care could enable a further third of cases to be treated.

 

 

 

 

The healthcare challenge

  • 11 million new cases of cancer diagnosed throughout the world each year.
  • 7 million deaths worldwide caused by cancer every year.
  • Breast cancer, lung cancer and cancer of the prostate and colon/rectum account for half of diagnosed cancers.
  • Of cancers affecting women, cervical cancer is the second greatest cause of death worldwide, after breast cancer.
  • The global economic impact of early death and cancer-related disability reached 895 billion dollars in 2008, equivalent to 1.5% of the world's gross domestic product (GDP).

Theranostic approach

  • Thanks to the advances in the knowledge of pharmacogenetics of cancers, a theranostic approach, also known as personalized medicine, is now possible through the combination of:
    • Targeted therapies, specific to a given biomarker,
    • Companion diagnostic tests allowing the selection of patients who will benefit from these treatments with better efficacy and optimal security.
  • The personalized medicine thus allows to treat each patient with the therapy that is adapted to him or her with a better efficacy, an optimal security and an improved level of response.
  • bioMérieux is committed for the development of high medical value theranostic tests allowing clinicians to select treatment according to the patient’s capacity to respond to it.
  • Thus, in 2013, bioMérieux launched the THxID™ BRAF kit*, its novel companion molecular test to detect two BRAF V600 gene mutations found in several cancers, including melanoma. Developed in collaboration with GSK, this companion diagnostic test is designed for patients with metastatic melanomas in order to help oncologists select the most appropriate treatment. Press Release

* CE-marked and FDA-approved

The role of in vitro diagnostics

  • Biological tests are used to reveal the changes occurring in cells and tissues as a result of cancer.
  • Cancer markers are substances secreted by cancerous cells and are detectable in biological fluids.
    • Their detection may indicate, to varying degrees of specificity, the presence of a malignant tumor or may indicate a particular organ that is affected.
      • For example: Levels of PSA (prostate-specific antigen) may be high in the event of either prostate cancer or a prostate infection.
    • Measurement of cancer markers enables a diagnosis to be made, and monitoring changes in their concentration can help to track the course of the disease and evaluate the effectiveness of treatment.
  • bioMérieux's research focuses on the most widespread forms of cancer (breast, prostate and colorectal), and on cancers caused by viruses. We offer solutions for screening and monitoring:

Type of cancer

Tumor markers offered by bioMérieux

Melanoma

BRAF V600 E and V600K mutations

Breast

CA 15-3, CEA

Cervical

Detection of active cancerous HPVs
(E6 / E7 mRNA)

Colorectal

CEA

Prostate

Total PSAs, free PSAs

Others: liver, ovaries, pancreas, choriocarcinoma, hematolymphoid.

AFP, CA 19-9, CA 125, hCG, beta2 – Microglobulin